Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

Inclusion Criteria: * Nephrotic Syndrome (NS) (FSGS, IMN or NS and type 2 DM) * atorvastatin * LDL C \>= 70 mg/dl or non-HDL C \>= 100 mg/dl * Plasma trigycerides \< 800 mg/dl. * Highly effective methods of contraception for pre-menopausal women * Post-menopausal women must be amenorrheic for at least 12 months. Exclusion Criteria: * homozygous FH * Fibrates within 6 weeks of screening visit * Uncontrolled hypothyroidism * Known history of hemorrhagic stroke * Known history of loss of function of PCSK9 * use of systemic corticosteroids unless used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks of randomization * Previous treatment with at least a single dose of alirocumab or any other anti-PCSK9 monoclonal antibody * Other conditions or situations per protocol * Laboratory findings or contraindications to background therapies * Warnings/precautions of use (when appropriate) as displayed in the respective national product labeling * Any currently known contra-indication to study drug, pregnancy or breastfeeding of infants.